Happy #MarathonMonday, Boston! Wishing all participants the best of luck! The #BostonMarathon is one of the hallmarks of our beloved Boston community. Let's stay #BostonStrong today and always.
Ikena Oncology
Biotechnology Research
Boston, Massachusetts 10,135 followers
Patient-directed oncology therapies across pathways relevant in tumor and immune cells
About us
Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. We have assembled an experienced and well-respected team of drug hunters, translational researchers, clinicians and entrepreneurs drawn from many of the largest innovators in biotechnology, supported by top-tier investors and partners, as well as world-class advisors, to advance and broaden our portfolio of novel, patient-directed oncology therapies.
- Website
-
https://www.ikenaoncology.com
External link for Ikena Oncology
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2016
- Specialties
- Targeted Oncology, cancer therapeutics development, small molecule drug design, cancer biology, and translational science and biomarkers
Locations
-
Primary
645 Summer Street
Suite 101
Boston, Massachusetts 02210, US
Employees at Ikena Oncology
-
Trupti Lingaraj
-
Mark Manfredi
President and CEO at Ikena Oncology
-
Maria Ng, CPA
Associate Director, Accounting at Ikena Oncology
-
Marissa Timothy
R&D Executive | Diverse Team Builder | Strategic CRO/Vendor Oversight | Site Selection and Management | Oncology | Immunology | Rare Disease
Updates
-
Ikena’s management team will present a corporate overview at the Stifel Financial Corp. 2024 Virtual Targeted Oncology Forum, taking place April 16-17. For more information and to register for the virtual webcast, visit: https://brnw.ch/21wIGym
-
-
Join us at the American Association for Cancer Research (AACR) 2024 Annual Meeting and check out our poster (#3296), highlighting our best-in-class MEK-RAF molecular glue, IK-595, and its potential as both a monotherapy and in combination. Click the link for more information and visit us on April 8 between 1:30pm-5pm PST: https://bit.ly/4abpxy0 #AACR2024 #AACR24
-